Novartis has high hopes for its radiotherapy Pluvicto. But as the Swiss pharma aims to move the drug into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that ...
Pluvicto is used to treat certain types of prostate cancer. It is a type of medicine called radioligand therapy. Common side effects include tiredness, dry mouth, nausea, decreased appetite, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results